Periodontitis and Rheumatoid Arthritis Oral Health Periodontitis and Rheumatoid Arthritis
Conditions
Interventions
After a full-mouth dental and periodontal examination, participants with periodontitis are randomized to one of two groups.
Those in the first group receive conventional periodontal treatment only at
Sponsors
Karolinska Institutet
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. =18 years of age 2. Fulfilling the 2010 ACR criteria for RA 3. Moderate to severe periodontitis, defined according to the classification criteria of the CDC Working Group meant for usage in Population-Based Surveillance of Periodontitis 4. Written informed consent to participate 5. Swedish national registration number
Exclusion criteria
Exclusion criteria: 1. Antibiotic treatment =3 months prior to inclusion into the study 2. Periodontal treatment (surgical or non-surgical) =3 months prior to inclusion into the study 3. Pregnancy 4. Simultaneous participation in other interventional studies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Rheumatoid arthritis (RA) disease activity is measured using the DAS28 score, HAQ score at baseline and one year 2. Periodontal parameters (such as probing pocket depth, clinical attachment loss) are measured using the methods of measurement of periodontal disease/parameters at baseline and months three, six, nine, and twelve | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 23/09/2025: 1. The microbial profile is assessed using sequencing technology throughout the study (the specific time points depend on the availability of the resources as well as the instruments at core facility) 2. Antibody levels (such as ACPA/RF, periodontal pathogens etc) are measured using multiplex immunoassay, nephelometry and/or ELISA technique at baseline and one year 3. Levels of inflammatory mediators are measured using Luminex immunoassay at baseline and one year 4. Metabolome profile measured using liquid chromatography–mass spectrometry (LC/MS) at baseline and one year Previous secondary outcome measures: 1. The microbial profile is assessed using sequencing technology throughout the study (the specific time points depend on the availability of the resources as well as the instruments at core facility) 2. Antibody levels (such as ACPA/RF, periodontal pathogens etc) are measured using multiplex immunoassay, nephelometry and/or ELISA technique at baseline and one year 3. Levels of inflammatory mediators are measured using Luminex immunoassay at baseline and one year | — |
Countries
Sweden
Outcome results
None listed